News
EVMN
14.65
+4.12%
0.58
Analysts Are Bullish on Top NA Stocks: BitGo Holdings, Inc. Class A (BTGO), Evommune, Inc. (EVMN)
TipRanks · 2d ago
Evercore ISI Keeps Their Buy Rating on Evommune, Inc. (EVMN)
TipRanks · 5d ago
Analysts Conflicted on These NA Names: TripAdvisor (TRIP), Evommune, Inc. (EVMN) and StandardAero, Inc. (SARO)
TipRanks · 5d ago
Weekly Report: what happened at EVMN last week (0803-0807)?
Weekly Report · 5d ago
Evommune Price Target Cut to $29.00/Share From $30.00 by RBC Capital
Dow Jones · 08/07 19:32
Evommune Is Maintained at Outperform by RBC Capital
Dow Jones · 08/07 19:32
RBC Capital Maintains Outperform on Evommune, Lowers Price Target to $29
Benzinga · 08/07 19:21
Evommune, Inc. GAAP EPS of -$0.89
Seeking Alpha · 08/07 13:59
Evommune price target lowered to $29 from $30 at RBC Capital
TipRanks · 08/07 12:21
RBC Capital Reaffirms Their Buy Rating on Evommune, Inc. (EVMN)
TipRanks · 08/07 11:08
Analysts Conflicted on These NA Names: Fiserv (FISV), Evommune, Inc. (EVMN) and Waystar Holding Corp. (WAY)
TipRanks · 08/07 08:40
Analysts Offer Insights on NA Companies: Evommune, Inc. (EVMN), LB Pharmaceuticals, Inc. (LBRX) and SpaceX (SPCX)
TipRanks · 08/03 11:20
Weekly Report: what happened at EVMN last week (0727-0731)?
Weekly Report · 08/03 10:30
HC Wainwright & Co. Reiterates Neutral on Evommune
Benzinga · 08/03 10:16
Evommune Launches Phase 2b Trial for EVO756 Migraine Drug
TipRanks · 07/30 12:29
Evommune initiates Phase 2b trial of EVO756
TipRanks · 07/30 12:22
Evommune participates in a conference call with Cantor
TipRanks · 07/29 20:28
Weekly Report: what happened at EVMN last week (0720-0724)?
Weekly Report · 07/27 10:35
Weekly Report: what happened at EVMN last week (0713-0717)?
Weekly Report · 07/20 10:31
Clear Street sees attractive point into Evommune after selloff
TipRanks · 07/16 14:00
More
Webull provides a variety of real-time EVMN stock news. You can receive the latest news about EVOMMUNE INC through multiple platforms. This information may help you make smarter investment decisions.
About EVMN
Evommune, Inc. is a clinical-stage biotechnology company developing therapies that target key drivers of chronic inflammatory diseases. Its initial clinical development programs are focusing on chronic spontaneous urticaria (CSU), atopic dermatitis (AD) and ulcerative colitis (UC). Its product candidates include EVO756 and EVO301. The Company's advanced clinical-stage product candidate, EVO756, is a potent and highly selective oral small molecule antagonist of MRGPRX2, a receptor predominantly found on mast cells and peripheral sensory neurons, which is initially being evaluated in Phase II trials for the treatment of CSU and AD. The Company's second clinical-stage product candidate, EVO301, is a long-acting fusion protein consisting of an IL-18 binding protein (BP) and an anti-serum albumin Fab-associated (SAFA) domain, which is being evaluated in Phase II trials for the treatment of AD and UC.